Currently, combining chemotherapy with Bruton tyrosine kinase inhibitors (BTKi) has demonstrated significant effectiveness in treating patients with diffuse large B-cell lymphoma. Orelabrutinib is a second-generation BTK inhibitor, and presently, there have been few reports of Orelabrutinib being used to treat DLBCL. We conducted a retrospective investigation to explore the safety and efficacy of Orelabrutinib in combination with chemotherapy or immunotherapy. The study comprised 19 patients with a median age of 61 years. The overall response rate (ORR) was 89.5% with a complete response (CR) rate of 73.7% and a partial response rate (PR) of 15.8%. The estimated 2-year overall survival (OS) and progression-free survival (PFS) rates were 78.6% (95%CI, 59.8%–100%) and 72.2% (95% CI, 52.4%–99.6%), respectively, with a median follow-up time of 11 months (range 2–24). The most prevalent grade 3 or 4 adverse events (AEs), neutropenia (52.6%), anemia (36.8%), thrombocytopenia (26.3%), febrile neutropenia (26.3%), and lung infection (10.5%), were the most common. Our results reveal that Orelabrutinib is an effective therapy for DLBCL patients. Furthermore, our first investigation of the Orelabrutinib application lays a foundation for larger retrospective studies.

目前，化疗与布鲁顿酪氨酸激酶抑制剂（BTKi）联合治疗已证明对治疗弥漫性大 B 细胞淋巴瘤患者具有显着疗效。奥布替尼是第二代BTK抑制剂，目前很少有奥布替尼用于治疗DLBCL的报道。我们进行了一项回顾性研究，以探讨奥布替尼联合化疗或免疫疗法的安全性和有效性。该研究包括 19 名患者，中位年龄为 61 岁。总缓解率（ORR）为89.5%，完全缓解率（CR）为73.7%，部分缓解率（PR）为15.8%。估计的 2 年总生存率 (OS) 和无进展生存率 (PFS) 分别为 78.6% (95% CI, 59.8%–100%) 和 72.2% (95% CI, 52.4%–99.6%)，中位随访时间为 11 个月（范围 2-24）。最常见的 3 级或 4 级不良事件 (AE) 为最常见的中性粒细胞减少症 (52.6%)、贫血 (36.8%)、血小板减少症 (26.3%)、发热性中性粒细胞减少症 (26.3%) 和肺部感染 (10.5%)。 。我们的结果表明奥布替尼是治疗 DLBCL 患者的有效疗法。此外，我们对奥布替尼应用的首次调查为更大规模的回顾性研究奠定了基础。